Trade Lenz Therapeutics Inc - LENZ CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.07
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.021485 %(-$1.07)Trade size with leverage ~ $5,000.00Money from leverage ~$4,000.00Go to platform: -0.02149%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.000738 %(-$0.04)Trade size with leverage ~ $5,000.00Money from leverage ~$4,000.00Go to platform: -0.00074%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.021485 %
  (-$1.07)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.000738 %
  (-$0.04)

Key Stats

• Prev. Close: 4.57
• Open: 4.65
• 1-Year Change: -88.14%
• Day's Range: 4.63 - 4.82

Trade Lenz Therapeutics Inc - LENZ

About Graphite Bio Inc

Graphite Bio, Inc. is clinical-stage, gene editing company. The Company is developing a new class of therapies to cure a range of serious and life-threatening diseases. The Company's gene editing platform allows to correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. The Company's lead product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. The Company's pipeline includes multiple programs including its gene replacement program, GPH201 for X-linked severe combined immunodeficiency syndrome (XSCID), a rare, life-threatening disease where multiple mutations in a single gene prevent normal immune system function, and targeted gene insertion program, GPH301 for Gaucher disease, and multiple additional programs in both HSCs and other cell types.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Graphite Bio Inc revenues was not reported. Net loss increased 3% to $70.8M. Higher net loss reflects Research and development - Balancing val increase from $9M to $35.2M (expense), General and administrative - Balancing v increase from $4.3M to $17.3M (expense), Stock-based Compensation in SGA increase from $54K to $5.2M (expense).